BeOne Medicines (NASDAQ:ONC) Shares Gap Up - What's Next?

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $247.08, but opened at $260.00. BeOne Medicines shares last traded at $257.67, with a volume of 111,639 shares changing hands.

Analyst Ratings Changes

ONC has been the subject of a number of recent research reports. Macquarie raised their target price on BeOne Medicines from $259.00 to $313.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Royal Bank Of Canada dropped their price objective on shares of BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. JPMorgan Chase & Co. lifted their target price on shares of BeOne Medicines from $311.00 to $317.00 and gave the stock an "overweight" rating in a research note on Monday, April 21st. Sanford C. Bernstein set a $259.00 price target on shares of BeOne Medicines in a research report on Thursday, March 13th. Finally, TD Securities reiterated a "buy" rating and issued a $334.00 price objective on shares of BeOne Medicines in a research note on Thursday, April 24th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, BeOne Medicines presently has an average rating of "Buy" and a consensus price target of $319.00.

BeOne Medicines Stock Performance

The stock has a 50 day moving average of $245.59. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71. The stock has a market cap of $27.90 billion, a price-to-earnings ratio of -68.42 and a beta of 0.30.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. On average, equities research analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Insider Activity

In other BeOne Medicines news, SVP Chan Henry Lee sold 700 shares of BeOne Medicines stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $256.11, for a total transaction of $179,277.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Xiaodong Wang sold 41,760 shares of the business's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $242.66, for a total value of $10,133,481.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 195,880 shares of company stock worth $49,871,511. 6.62% of the stock is currently owned by insiders.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.